pravibismane
Small moleculeexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2016 (NCT02436876)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
- Mol. weight
- 694.52 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314962 ↗
Also known as
- mbn-101
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05174806 | Phase 2 | Jun 13, 2022 | Microbion Corporation, United States Navy |
| NCT02723539 | Phase 1/Phase 2 (Phase 2) | Mar 3, 2017 | Microbion Corporation |
| NCT02436876 | Phase 2 | Jan 1, 2016 | Department of Defense, Medpace, Inc., Microbion Corporation, University of California, San Francisco, University of Pennsylvania |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Microbion Corporation | For profit | 3 | 3 | 1 | 2016 |
| Department of Defense | Government | 1 | 0 | 1 | 2016 |
| Medpace, Inc. | For profit | 1 | 0 | 1 | 2016 |
| United States Navy | Government | 1 | 0 | 1 | 2022 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Pennsylvania | Academic/Hospital | 1 | 0 | 1 | 2016 |
6 organizations
Page 1 / 1